romosozumab
AssetAlso AMG 785
Inhibits sclerostin to promote bone formation and reduce bone resorption
- Stage
- Approved
- Modality
- Antibody
- Target
- SOST
- 9
- Indications
- 32
- Trials
- 2
- Developers
Indications
9Osteoporosis
Approved, accessdata.fda.gov, 7 Oct 2026
Osteogenesis imperfecta
Phase 3, Active not recruiting, NCT05972551, clinicaltrials.gov, 7 Oct 2026
Osteoporosis
Phase 3, Completed, NCT01631214, clinicaltrials.gov, 7 Oct 2026
6 more
In the full profile
- Targets and what it contains1
- Owner and partners2
- Trials32
- Evidence for its targets2
- Competitors2
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 7 Oct 2026, 14 sources